PanGen Biotech Inc (222110) — Financial Flexibility Index
PanGen Biotech Inc (222110) has a Financial Flexibility Index of -1.27x as of September 2025. Free cash flow of ₩-3.47 Billion (operating CF ₩-3.66 Billion minus capex ₩196.18 Million) represents -1% of total liabilities (₩2.74 Billion). Check PanGen Biotech Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
PanGen Biotech Inc Financial Flexibility Index (2014–2024)
Historical Financial Flexibility Index trend for PanGen Biotech Inc across 11 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of PanGen Biotech Inc.
Annual Financial Flexibility Index for PanGen Biotech Inc (2014–2024)
Year-by-year free cash flow to debt coverage for PanGen Biotech Inc. Explore how well can PanGen Biotech Inc service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.60x | ₩3.36 Billion | ₩2.99 Billion | ₩5.64 Billion | ▲ +264.4% |
| 2023 | -0.36x | ₩-2.97 Billion | ₩-3.45 Billion | ₩8.18 Billion | ▲ +54.8% |
| 2022 | -0.80x | ₩-2.77 Billion | ₩-3.50 Billion | ₩3.45 Billion | ▼ -838.2% |
| 2021 | -0.09x | ₩-1.90 Billion | ₩-3.32 Billion | ₩22.18 Billion | ▲ +51.8% |
| 2020 | -0.18x | ₩-3.93 Billion | ₩-4.68 Billion | ₩22.10 Billion | ▼ -29.1% |
| 2019 | -0.14x | ₩-2.84 Billion | ₩-3.66 Billion | ₩20.66 Billion | ▲ +43.6% |
| 2018 | -0.24x | ₩-4.55 Billion | ₩-5.61 Billion | ₩18.67 Billion | ▼ -172.6% |
| 2017 | 0.34x | ₩1.44 Billion | ₩-657.84 Million | ₩4.28 Billion | ▲ +179.8% |
| 2016 | -0.42x | ₩-880.81 Million | ₩-4.35 Billion | ₩2.09 Billion | ▼ -15542.4% |
| 2015 | 0.00x | ₩-25.14 Million | ₩-1.61 Billion | ₩9.34 Billion | ▲ +97.9% |
| 2014 | -0.13x | ₩-792.03 Million | ₩-1.34 Billion | ₩6.18 Billion | — |